AU2018250312C1 - Bioorthogonal compositions - Google Patents

Bioorthogonal compositions Download PDF

Info

Publication number
AU2018250312C1
AU2018250312C1 AU2018250312A AU2018250312A AU2018250312C1 AU 2018250312 C1 AU2018250312 C1 AU 2018250312C1 AU 2018250312 A AU2018250312 A AU 2018250312A AU 2018250312 A AU2018250312 A AU 2018250312A AU 2018250312 C1 AU2018250312 C1 AU 2018250312C1
Authority
AU
Australia
Prior art keywords
compound
4alkylene
agent
tco
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018250312A
Other languages
English (en)
Other versions
AU2018250312B2 (en
AU2018250312A1 (en
Inventor
Jose Manuel MEJIA ONETO
Ethan Miller
Maksim Royzen
Sangeetha SRINIVASAN
Nathan Yee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tambo Inc
Research Foundation of the State University of New York
Original Assignee
Tambo Inc
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tambo Inc, Research Foundation of the State University of New York filed Critical Tambo Inc
Publication of AU2018250312A1 publication Critical patent/AU2018250312A1/en
Application granted granted Critical
Publication of AU2018250312B2 publication Critical patent/AU2018250312B2/en
Publication of AU2018250312C1 publication Critical patent/AU2018250312C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/04—Alginic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Materials Engineering (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2018250312A 2017-04-07 2018-04-06 Bioorthogonal compositions Active AU2018250312C1 (en)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US201762483121P 2017-04-07 2017-04-07
US201762483163P 2017-04-07 2017-04-07
US201762483081P 2017-04-07 2017-04-07
US62/483,163 2017-04-07
US62/483,081 2017-04-07
US62/483,121 2017-04-07
US201762507973P 2017-05-18 2017-05-18
US62/507,973 2017-05-18
US201762515948P 2017-06-06 2017-06-06
US62/515,948 2017-06-06
US201762568586P 2017-10-05 2017-10-05
US62/568,586 2017-10-05
US201762609943P 2017-12-22 2017-12-22
US62/609,943 2017-12-22
US201862623245P 2018-01-29 2018-01-29
US201862623329P 2018-01-29 2018-01-29
US62/623,329 2018-01-29
US62/623,245 2018-01-29
US201862626978P 2018-02-06 2018-02-06
US62/626,978 2018-02-06
PCT/US2018/026551 WO2018187740A1 (en) 2017-04-07 2018-04-06 Bioorthogonal compositions

Publications (3)

Publication Number Publication Date
AU2018250312A1 AU2018250312A1 (en) 2019-10-31
AU2018250312B2 AU2018250312B2 (en) 2022-03-17
AU2018250312C1 true AU2018250312C1 (en) 2024-08-22

Family

ID=62092258

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018250312A Active AU2018250312C1 (en) 2017-04-07 2018-04-06 Bioorthogonal compositions

Country Status (7)

Country Link
US (2) US11253600B2 (https=)
EP (2) EP3606559B1 (https=)
JP (1) JP7405616B2 (https=)
CN (1) CN111093708B (https=)
AU (1) AU2018250312C1 (https=)
ES (1) ES2983582T3 (https=)
WO (1) WO2018187740A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6823067B2 (ja) 2015-09-10 2021-01-27 タンボ・インコーポレイテッド 生体直交型組成物
WO2020064844A1 (en) * 2018-09-26 2020-04-02 Ascendis Pharma A/S Treatment of infections
IL282114B2 (en) * 2018-10-10 2025-05-01 Tambo Inc Processes for preparing functional cyclooctanes
US12194023B2 (en) 2018-11-29 2025-01-14 The Research Foundation For The State University Of New York Compositions and methods for modular control of bioorthogonal ligation
JP7660525B2 (ja) * 2019-06-17 2025-04-11 タグワークス ファーマシューティカルス ビー．ブイ． イン・ビボで生体分子から標識を切断する為の剤
AU2020310853A1 (en) * 2019-07-05 2022-01-27 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
SE2050204A1 (en) * 2020-02-24 2021-08-25 Oboe Ipr Ab A system and method for releasing a species
CN113321702B (zh) * 2020-02-28 2022-08-05 国家纳米科学中心 一种单甲基澳瑞他汀f甲酯前药及其制备方法和应用
EP4295917A3 (en) 2020-08-07 2024-02-28 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
EP4422693A1 (en) 2021-10-29 2024-09-04 Tambo, Inc. Trans-cyclooctene conjugates
JP2024542021A (ja) 2021-10-29 2024-11-13 タンボ・インコーポレイテッド ペイロードのｉｎ ｖｉｖｏ標的化送達用のテトラジンコンジュゲート
US20250009890A1 (en) * 2021-11-05 2025-01-09 Tambo, Inc. Trans-cyclooctene-modified bispecific antibodies
CN114478828B (zh) * 2021-12-08 2023-03-31 深圳先进技术研究院 一种循环肿瘤细胞的检测材料、检测器以及检测方法
EP4669357A1 (en) 2023-02-21 2025-12-31 Tambo, Inc. TRANS-CYCLOOCTENE CONJUGATES
EP4704904A1 (en) 2023-05-04 2026-03-11 Tambo, Inc. Tetrazine-based targeting agents for in vivo delivery of a payload
CN121419790A (zh) 2023-05-18 2026-01-27 坦博公司 反式环辛烯修饰的靶向性蛋白质降解剂缀合物
WO2025059685A1 (en) 2023-09-15 2025-03-20 Tambo, Inc. Methods for in vivo targeted delivery of a payload
CN119019576A (zh) * 2024-09-02 2024-11-26 齐鲁工业大学(山东省科学院) 纤维素基甲醛荧光探针及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017044983A1 (en) * 2015-09-10 2017-03-16 Shasqi, Inc. Bioorthogonal compositions

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658592A (en) 1994-05-13 1997-08-19 Kuraray Co., Ltd. Medical crosslinked polymer gel of carboxylic polysaccharide and diaminoalkane
JP4283666B2 (ja) 2001-06-21 2009-06-24 クローンテック ラボラトリーズ インク． 水溶性ポリマー金属イオンアフィニティ組成物、およびその使用方法
US20060153893A1 (en) 2002-04-08 2006-07-13 Denki Kagaku Kogyo Kabushiki Kaisha Therapeutic composition for bone infectious disease
US7445894B2 (en) 2002-05-03 2008-11-04 Molecular Probes, Inc. Compositions and methods for detection and isolation of phosphorylated molecules
EP1942950A2 (en) 2005-11-01 2008-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Biodegradable composite for internal local radiotherapy
EP1867638A1 (de) 2006-06-16 2007-12-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verfahren zur kovalenten Verknüpfung zweier Moleküle mittels Diels-Alder-Reaktion mit inversem Elektronenbedarf
US8398956B2 (en) 2007-01-11 2013-03-19 Immunomedics, Inc. In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
US8236949B2 (en) 2007-07-17 2012-08-07 University Of Delaware Tetrazine-based bio-orthogonal coupling reagents and methods
CN103169973A (zh) * 2007-11-12 2013-06-26 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
WO2011127149A1 (en) 2010-04-06 2011-10-13 University Of Utah Research Foundation Controlled release combination biomaterials
JP5574083B2 (ja) 2008-08-01 2014-08-20 アンタイス エス．エイ． 高い残留性及び容量を与える高い能力を有する注入可能なヒドロゲル
CN102271712B (zh) 2008-10-31 2015-11-25 通用医疗公司 用于将物质递送至生物靶标的组合物和方法
CA2742846A1 (en) 2008-11-17 2010-05-20 Enzon Pharmaceuticals, Inc. Releasable fusogenic lipids for nucleic acids delivery systems
EP2419142B1 (en) 2009-04-16 2020-01-15 Tagworks Pharmaceuticals B.V. Pretargeting kit, method and agents used therein
EP2595967B1 (en) 2010-07-23 2016-03-23 University Of Delaware Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes
RU2013121799A (ru) 2010-10-14 2014-11-20 Конинклейке Филипс Электроникс Н.В. Набор для претаргетинга, способ и агенты, применяемые в нем
WO2012074840A2 (en) 2010-11-22 2012-06-07 The General Hospital Corporation Compositions and methods for in vivo imaging
RU2013133813A (ru) 2010-12-21 2015-01-27 Конинклейке Филипс Электроникс Н.В. Средства для выведения биомолекул из кровотока
EP2522369A1 (en) 2011-05-09 2012-11-14 Koninklijke Philips Electronics N.V. Pretargeting kit, method and agents used therein
JP6215194B2 (ja) 2011-05-16 2017-10-18 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 生体直交型薬物活性化
EP2716662A4 (en) 2011-05-31 2014-11-19 Univ Tokyo HYDROGEL AND METHOD FOR ITS MANUFACTURE
ES2393602B1 (es) 2011-06-09 2013-10-02 Universidad Complutense De Madrid Materiales biocerámicos para el tratamiento de la osteomielitis.
WO2013115885A2 (en) 2011-11-22 2013-08-08 The Regents Of The University Of Michigan Synthesizing functionalized dendrimers within biological settings
CN117462693A (zh) 2012-02-27 2024-01-30 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
US9206271B2 (en) 2012-03-25 2015-12-08 Wisconsin Alumni Research Foundation Fully backbone degradable and functionalizable polymers derived from the ring-opening metathesis polymerization (ROMP)
US10274490B2 (en) 2012-06-12 2019-04-30 The General Hospital Corporation Magnetic labeling of bacteria
US9902705B2 (en) 2012-10-24 2018-02-27 The General Hospital Corporation Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
WO2014081303A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Chemically cleavable group
US20150297741A1 (en) 2012-11-22 2015-10-22 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
WO2014081300A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Channel protein activatable liposomes
WO2014081299A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Activatable liposomes
WO2014117001A1 (en) 2013-01-25 2014-07-31 Memorial Sloan-Kettering Cancer Center Tetrazines/trans-cyclooctenes in solid phase synthesis of labeled peptides
WO2014138186A1 (en) 2013-03-05 2014-09-12 The Johns Hopkins University Bioorthogonal two-component delivery systems for enhanced internalization of nanotherapeutics
DK2964224T3 (en) 2013-03-08 2024-10-14 Polyactiva Pty Ltd Polymer conjugate for delivery of a bioactive agent
EP3008201B1 (en) 2013-06-12 2019-08-07 The General Hospital Corporation Methods for multiplexed detection of target molecules and uses thereof
US10130711B2 (en) 2013-06-19 2018-11-20 The Regents Of The University Of California Chemical structures for localized delivery of therapeutic agents
CA2939265A1 (en) 2014-02-10 2015-08-13 Mcmaster University Targeted molecular imaging contrast agents
ES2880468T3 (es) 2014-03-14 2021-11-24 Univ California Conjugados de TCO y métodos para el suministro de agentes terapéuticos
EP3125866B1 (en) 2014-04-04 2021-03-03 President and Fellows of Harvard College Refillable drug delivery devices and methods of use thereof
ES2951908T3 (es) 2014-04-04 2023-10-25 Harvard College Hidrogeles reticulados por química clic y métodos de uso
WO2016014799A1 (en) * 2014-07-23 2016-01-28 University Of Iowa Research Foundation Epidermal growth factor and blockade of immune checkpoints in cancer immunotherapy
JP2018519327A (ja) 2015-06-29 2018-07-19 ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． 治療用組成物、組合せ物および使用の方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017044983A1 (en) * 2015-09-10 2017-03-16 Shasqi, Inc. Bioorthogonal compositions

Also Published As

Publication number Publication date
JP7405616B2 (ja) 2023-12-26
US20210128733A1 (en) 2021-05-06
WO2018187740A1 (en) 2018-10-11
JP2020516621A (ja) 2020-06-11
US11253600B2 (en) 2022-02-22
CN111093708A (zh) 2020-05-01
EP3606559C0 (en) 2024-06-05
EP3606559B1 (en) 2024-06-05
US20220168426A1 (en) 2022-06-02
ES2983582T3 (es) 2024-10-23
EP4458896A3 (en) 2025-01-08
US20250255970A1 (en) 2025-08-14
CN111093708B (zh) 2024-10-29
EP4458896A2 (en) 2024-11-06
EP3606559A1 (en) 2020-02-12
AU2018250312B2 (en) 2022-03-17
US12296017B2 (en) 2025-05-13
AU2018250312A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
US12296017B2 (en) Bioorthogonal compositions
US12527874B2 (en) Bioorthogonal compositions
JP7622031B2 (ja) トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
US12611461B2 (en) Bioorthogonal compositions
HK40118230A (en) Bioorthogonal compositions
US20250049936A1 (en) Bioorthogonal compositions
EP4713022A1 (en) Trans-cyclooctene-modified targeted protein degrader conjugates
WO2024178155A1 (en) Trans-cyclooctene conjugates

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20 MAR 2024

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 20 MAR 2024